{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Methylprednisolone+Tablet&page=2", "query": { "intervention": "Methylprednisolone Tablet", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Methylprednisolone+Tablet&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T23:08:03.991Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04493853", "title": "Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hormone-Sensitive Prostate Cancer" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Abiraterone Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "MALE", "summary": "18 Years to 130 Years · Male only" }, "enrollment_count": 1012, "start_date": "2020-07-13", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-29T23:08:03.991Z", "location_count": 33, "location_summary": "Tucson, Arizona • La Jolla, California • Orange, California + 29 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493853" }, { "nct_id": "NCT00240994", "title": "Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Failure, Chronic", "Kidney Transplantation", "Immunosuppression" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "20 Years", "sex": "ALL", "summary": "1 Year to 20 Years" }, "enrollment_count": 35, "start_date": "2005-01", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2017-01-02", "last_synced_at": "2026-09-29T23:08:03.991Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00240994" }, { "nct_id": "NCT00023244", "title": "Steroid Withdrawal in Pediatric Kidney Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "End-Stage Renal Disease" ], "interventions": [ { "name": "Basiliximab", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Bactrim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "20 Years", "sex": "ALL", "summary": "1 Day to 20 Years" }, "enrollment_count": 274, "start_date": "2001-01", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2016-10-21", "last_synced_at": "2026-09-29T23:08:03.991Z", "location_count": 18, "location_summary": "Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023244" }, { "nct_id": "NCT07158476", "title": "Efficacy of Methylprednisolone for Pain Control After ACL Repair", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "ACL Surgery", "Pain Management" ], "interventions": [ { "name": "Meloxicam 15 mg", "type": "DRUG" }, { "name": "Medrol 4 MG Oral Tablet Includes Medrol Dosepak", "type": "DRUG" }, { "name": "Gabapentin 300 mg", "type": "DRUG" }, { "name": "Hydrocodone 5Mg/Acetaminophen 325Mg Tab", "type": "DRUG" }, { "name": "Ketorolac 10 Mg Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Louis University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "13 Years to 50 Years" }, "enrollment_count": 90, "start_date": "2025-10-21", "completion_date": "2031-09", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-09-29T23:08:03.991Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07158476" }, { "nct_id": "NCT05867329", "title": "Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ulcerative Colitis Acute" ], "interventions": [ { "name": "Cyclosporine Injection (IV)", "type": "DRUG" }, { "name": "Cyclosporine Oral Product", "type": "DRUG" }, { "name": "Upadacitinib Extended Release Oral Tablet", "type": "DRUG" }, { "name": "Intravenous Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone Oral Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Berinstein, Jeffrey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 700, "start_date": "2023-09-30", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-29T23:08:03.991Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867329" }, { "nct_id": "NCT04666129", "title": "Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer", "Metastatic Castration-Sensitive Prostate Cancer", "Non-Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 48, "start_date": "2021-02-18", "completion_date": "2024-05-28", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-09-29T23:08:03.991Z", "location_count": 16, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04666129" }, { "nct_id": "NCT07070882", "title": "Oral Steroid Taper After Total Knee Arthroplasty", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Osteoarthritis, Knee" ], "interventions": [ { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2025-06-20", "completion_date": "2027-06-20", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-29T23:08:03.991Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07070882" }, { "nct_id": "NCT01308580", "title": "Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Cabazitaxel (XRP6258)", "type": "DRUG" }, { "name": "Prednisone (or Prednisolone)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1200, "start_date": "2011-04", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-09-29T23:08:03.991Z", "location_count": 21, "location_summary": "Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 18 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Bernardino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01308580" }, { "nct_id": "NCT06561035", "title": "Reduce Opiate Exposure With ACL Surgery", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anterior Cruciate Ligament Injuries" ], "interventions": [ { "name": "Opiate Sparing", "type": "DRUG" }, { "name": "Opiate Based", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Campbell Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "14 Years to 85 Years" }, "enrollment_count": 56, "start_date": "2024-09-01", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-09-29T23:08:03.991Z", "location_count": 3, "location_summary": "Skokie, Illinois • Cincinnati, Ohio • Memphis, Tennessee", "locations": [ { "city": "Skokie", "state": "Illinois" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06561035" }, { "nct_id": "NCT03732820", "title": "Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "olaparib", "type": "DRUG" }, { "name": "abiraterone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 895, "start_date": "2018-10-31", "completion_date": "2027-02-05", "has_results": true, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-29T23:08:03.991Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Clovis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03732820" } ] }